/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

Aditxt Inc

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$2.83 0.1089(10.89%) ADTX at 04 Dec 2025 04:25 PM Biotechnology
Lowest Today 2.49
Highest Today 2.9
Today’s Open 2.495
Prev. Close 2.48
52 Week High 10311.25
52 Week Low 2.36
Day’s Range: Low 2.49 High 2.9
52-Week Range: Low 2.36 High 10311.25
1 day return -
1 Week return -27.3
1 month return -47.67
3 month return +193.99
6 month return +78.89
1 year return +701.33
3 year return -95.99
5 year return -99.92
10 year return -

Institutional Holdings

Virtu Financial LLC 0.42

HRT FINANCIAL LLC 0.27

Fidelity Extended Market Index 0.22

Tower Research Capital LLC 0.08

Spartan Total Market Index Pool G 0.02

Morgan Stanley - Brokerage Accounts 0.01

UBS Group AG 0.00

SBI Securities Co Ltd 0.00

IFP Advisors, LLC 0.00

Bank of America Corp 0.00

Advisor Group Holdings, Inc. 0.00

Goldman Sachs Group Inc 0.00

Group One Trading, LP 0.00

Harwood Advisory Group, LLC 0.00

JONES FINANCIAL COMPANIES LLLP 0.00

NT Ext Eq Mkt Indx Fd DC Lend T3 0.00

NT Ext Equity Mkt Idx Fd - DC - NL - T2 0.00

NT Ext Equity Mkt Idx Fd - L 0.00

NT Ext Equity Mkt Idx Fd - NL 0.00

State St US Extended Mkt Indx NL Cl C 0.00

Market Status

Strong Buy: 0

Buy: 1

Hold: 0

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 1.39 M

PB Ratio 0.2919

PE Ratio 0.0

Enterprise Value 7.64 M

Total Assets 32.14 M

Volume 709074

Company Financials

Annual Revenue FY23:749475 0.7M, FY22:933715 0.9M, FY21:105034 0.1M, FY20:0 0.0M, FY19:0 0.0M

Annual Profit FY23:108340 0.1M, FY22:166936 0.2M, FY21:27055 0.0M, FY20:null 0.0M, FY19:null 0.0M

Annual Net worth FY23:-29595792 -29.6M, FY22:-28193814 -28.2M, FY21:-48309931 -48.3M, FY20:-9459308 -9.5M, FY19:-5829658 -5.8M

Quarterly Revenue Q3/2025:748 0.0M, Q2/2025:1004 0.0M, Q1/2025:1018 0.0M, Q3/2024:6854 0.0M, Q2/2024:44276 0.0M

Quarterly Profit Q3/2025:-67515 -0.1M, Q2/2025:-67882 -0.1M, Q1/2025:284 0.0M, Q3/2024:-460682 -0.5M, Q2/2024:21142 0.0M

Quarterly Net worth Q3/2025:-24045405 -24.0M, Q2/2025:-7256808 -7.3M, Q1/2025:-5710309 -5.7M, Q3/2024:-6940512 -6.9M, Q2/2024:-7549619 -7.5M

Fund house & investment objective

Company Information Aditxt, Inc., a commercial-stage company, discovers and develops products in the areas of immune health, precision health, population health, women's health, and neurologic health. The company develops AditxtScore that enable individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its tissues. It also develops ADI-100 for skin grafting, psoriasis, type 1 diabetes, and multiple sclerosis. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Mountain View, California.

Organisation Biotechnology

Employees 26

Industry Biotechnology

CEO Mr. Amro A. Albanna

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow